Cost-effectiveness analysis of liposomal irinotecan in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas in Greece.
| Publicado en: | Expert Review of Pharmacoeconomics & Outcomes Research pp. 1 - 10 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
Taylor & Francis Ltd
Aug2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=196112644&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 196112644 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14737167 1IHY jtl: Expert Review of Pharmacoeconomics & Outcomes Research issn: 14737167 maglogo: N pubinfo: dt: Aug2026 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 196112644 10.1080/14737167.2026.2718413 196112644 ppf: 1 ppct: 9 formats: tig: atl: Cost-effectiveness analysis of liposomal irinotecan in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas in Greece. aug: au: Gourzoulidis, George Chotzagiannoglou, Vassiliki Angelopoulou, Andriani Solakidou, Eleana Tzanetakos, Charalampos affil: Health Through Evidence GP sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|